Agenus shared a post on LinkedIn:
“At ASCO25, we shared new data highlighting botensilimab’s immune activation in MSS colorectal cancer—a common, treatment-resistant form of the disease. These findings offer new insight into how patients with colorectal cancer may respond at the immune level.
